Rosen Law Firm Encourages Nektar Therapeutics Investors to Secure Counsel Before Deadline

Investors who purchased Nektar securities during the Class Period may be entitled to compensation through a contingency fee arrangement.

Apr. 6, 2026 at 10:35pm

Got story updates? Submit your updates here. ›

A photorealistic studio still life featuring a stack of legal documents, a gavel, and a pair of reading glasses arranged on a clean, monochromatic background, symbolizing the abstract concepts of corporate strategy, finance, and legal proceedings.A meticulous legal process aims to hold a pharmaceutical company accountable for misleading investors.NYC Today

The Rosen Law Firm, a global investor rights law firm, is reminding purchasers of Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025 of the important May 5, 2026 lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that Nektar made false and/or misleading statements about the REZOLVE-AA trial, which is likely to have a significant negative impact on the trial's results.

Why it matters

The lawsuit claims that when the true details about the REZOLVE-AA trial entered the market, investors suffered damages. The Rosen Law Firm is encouraging investors to secure counsel before the important May 5, 2026 lead plaintiff deadline, as they believe the firm has a track record of success in leadership roles in securities class actions.

The details

According to the lawsuit, the defendants made false and/or misleading statements and/or failed to disclose that: (1) enrollment in the REZOLVE-AA trial had not followed applicable instructions and protocol standards; (2) the foregoing was likely to have a significant negative impact on the REZOLVE-AA trial's results; (3) accordingly, the REZOLVE-AA trial's overall integrity and prospects were overstated; and (4) as a result, defendants' public statements were materially false and misleading at all relevant times.

  • The Class Period is from February 26, 2025 to December 15, 2025, both dates inclusive.
  • The lead plaintiff deadline is May 5, 2026.

The players

Rosen Law Firm

A global investor rights law firm that represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Nektar Therapeutics

A biopharmaceutical company that develops innovative medicines in areas of high unmet medical need.

Got photos? Submit your photos here. ›

What they’re saying

“We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition.”

— Laurence Rosen, Founding Partner, Rosen Law Firm

What’s next

To join the Nektar class action, investors can go to the Rosen Law Firm's website or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. The deadline to move the Court to serve as lead plaintiff is May 5, 2026.

The takeaway

This case highlights the importance for investors to carefully select qualified legal counsel with a proven track record when participating in securities class action lawsuits. The Rosen Law Firm's experience and success in this area could be beneficial for Nektar investors seeking compensation.